LLY
Eli Lilly and Company
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
Market Cap: 93.6 Billion
Primary Exchange: New York Stock Exchange
Website: http://www.lilly.com
Shares Outstanding: 1.1 Billion
Float: 1.1 Billion
Dividend: 2.25 (2.65%)
Beta: 0.273926
Sector: Healthcare
Industry: Drug Manufacturers
Ethical Flags
Longest drawdown: 778 trading days
From: 2015-09-17 To: 2018-07-17
Lowest Point:
Akero Therapeutics Readies $75 Million IPO
via: SeekingAlpha at 2019-06-13 09:11:26:000
Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...
Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript)
via: SeekingAlpha at 2019-06-12 15:33:05:000
Eli Lilly and Company (LLY) Goldman Sachs 40th Annual Global Helathcare Conference June 11, 2019 4:20 PM ET Company Participants Josh Smiley Chief Financial Officer Conference Call Participants Terence Flynn Goldman Sachs Presentation Terence Flynn O… read more...
These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors
via: SeekingAlpha at 2019-06-11 10:29:57:000
Actionable Conclusions (1-10): Brokers Predict 16.65% To 39.75% Net Gains To June 2020 Three of the ten top Fortune 500 Best Dividend Investments by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...
These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors
via: SeekingAlpha at 2019-06-11 10:29:57:000
Actionable Conclusions (1-10): Brokers Predict 16.65% To 39.75% Net Gains To June 2020 Three of the ten top Fortune 500 Best Dividend Investments by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...
Lilly's Taltz shows long-term benefit in psoriasis study
via: SeekingAlpha at 2019-06-11 06:30:12:000
Five-year data from a Phase 3 clinical trial evaluating Eli Lilly's ( LLY +0.4% ) Taltz (ixekizumab) in patients with moderate-to-severe plaque psoriasis showed a durable treatment benefit. The results are being presented at the World Congress of Dermatology in Milan. More news … read more...
Lilly's Taltz shows long-term benefit in psoriasis study
via: SeekingAlpha at 2019-06-11 06:30:12:000
Five-year data from a Phase 3 clinical trial evaluating Eli Lilly's ( LLY +0.4% ) Taltz (ixekizumab) in patients with moderate-to-severe plaque psoriasis showed a durable treatment benefit. The results are being presented at the World Congress of Dermatology in Milan. More news … read more...
Zymeworks: Leader In Bispecifics Space Makes Substantial Headway
via: SeekingAlpha at 2019-06-11 02:07:59:000
Shares of Zymeworks ( ZYME ) have nearly doubled since I suggested that readers "buy the dip" in February 2018. In that article, I pointed out that a bet on the stock was not merely a wager on prospects for lead program ZW25, but also on its impressive platform technologies with several part… read more...
Zymeworks: Leader In Bispecifics Space Makes Substantial Headway
via: SeekingAlpha at 2019-06-11 02:07:59:000
Shares of Zymeworks ( ZYME ) have nearly doubled since I suggested that readers "buy the dip" in February 2018. In that article, I pointed out that a bet on the stock was not merely a wager on prospects for lead program ZW25, but also on its impressive platform technologies with several part… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
via: PR Newswire at 2019-06-10 23:00:00:000
INDIANAPOLIS , June 11, 2019 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high l… read more...
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
via: PR Newswire at 2019-06-10 23:00:00:000
INDIANAPOLIS , June 11, 2019 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high l… read more...
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
via: PR Newswire at 2019-06-10 17:30:00:000
RIDGEFIELD, Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ --Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA trial demonstrating that Tradjenta (linagliptin) did not increase cardiovascular risk compared… read more...
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
via: PR Newswire at 2019-06-10 17:30:00:000
RIDGEFIELD, Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ --Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA trial demonstrating that Tradjenta (linagliptin) did not increase cardiovascular risk compared… read more...
Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity
via: SeekingAlpha at 2019-06-10 14:12:04:000
Xeris Pharmaceuticals ( XERS ) shares sold off prior to Gvokes PDUFA date on June 10 th . However, the selling pressured subsided dramatically after the company reported that on June 5 th , the FDA extended Gvokes PDUFA date by 90 days due to a major amendment to the NDA. An FD… read more...
Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript)
via: SeekingAlpha at 2019-06-10 11:56:13:000
Eli Lilly and Company (LLY) ADA Presentations and Diabetes Portfolio Conference Call June 10, 2019, 10:00 AM ET Company Participants Mike Czapar - IR Enrique Conterno - President, Lilly Diabetes and Lilly USA Ilya Yuffa - VP, U.S. Diabetes Brad Woodward - Global Development Lea… read more...
New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
via: PR Newswire at 2019-06-10 09:00:00:000
RIDGEFIELD , Conn.and INDIANAPOLIS , June 10,2019 /PRNewswire/ --A new post-hoc analysis of data from the EMPA-REG OUTCOME trial indicates a consistent effect of Jardiance (empagliflozin) on reducing cardiovascular and renal risk in adults with type 2 diab… read more...
ADA Presentations and Diabetes Portfolio
via: SeekingAlpha at 2019-06-10 05:38:16:000
The following slide deck was published by Eli Lilly and Company in conjunction with this Read more … read more...
Lilly's Trulicity reduced CV risk in large-scale T2D study
via: SeekingAlpha at 2019-06-10 05:17:16:000
Results from the large-scale Phase 3 REWIND study evaluating the effects of Eli Lilly's (NYSE: LLY ) once-weekly Trulicity (dulaglutide) on reducing cardiovascular (CV) risk in people with type 2 diabetes (T2D) showed a sustained benefit regardless of the presence of established CV dise… read more...
Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO
via: SeekingAlpha at 2019-06-10 00:47:20:000
Deals and Financings Frontage Holdings, a US-China CRO, raised $205 million in a Hong Kong IPO at a market capitalization of $820 million. It moved 4.5% higher on its first day of trading. According to Frontage, it will allocate 20% of the proceeds to meet increased demand, 40% for organic e… read more...
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
via: PR Newswire at 2019-06-09 15:30:00:000
INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular events (MACE), a composite endpoint of non-fatal myocardial infarction (heart attac… read more...
Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions
via: PR Newswire at 2019-06-09 07:30:00:000
INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data from th… read more...
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79?? Scientific Sessions®
via: PR Newswire at 2019-06-08 16:30:00:000
INDIANAPOLIS , June 8, 2019 /PRNewswire/ -- Results from several studies ofEli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes. Early researc… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2019-08-14 | 2019-09-10 | 2019-08-15 | 2019-06-19 | 0.645 | No Change QoQ | |||
| 2019-05-16 | 2019-06-10 | 2019-05-17 | 2019-05-06 | 0.645 | No Change QoQ | |||
| 2019-02-14 | 2019-03-08 | 2019-02-15 | 2018-12-19 | 0.645 | Increase | |||
| 2018-11-14 | 2018-12-10 | 2018-11-15 | 2018-10-15 | 0.5625 | No Change QoQ | |||
| 2018-08-14 | 2018-09-10 | 2018-08-15 | 2018-06-18 | 0.5625 | No Change QoQ | |||
| 2018-05-16 | 2018-06-08 | 2018-05-17 | 2018-05-07 | 0.5625 | No Change QoQ | |||
| 2018-02-14 | 2018-03-09 | 2018-02-15 | 2017-12-11 | 0.5625 | Increase | |||
| 2017-11-14 | 2017-12-08 | 2017-11-15 | 2017-10-16 | 0.52 | No Change QoQ | |||
| 2017-08-11 | 2017-09-08 | 2017-08-15 | 2017-06-19 | 0.52 | No Change QoQ | |||
| 2017-05-11 | 2017-06-09 | 2017-05-15 | 2017-05-01 | 0.52 | No Change QoQ | |||
| 2017-02-13 | 2017-03-10 | 2017-02-15 | 2016-12-12 | 0.52 | Increase | |||
| 2016-11-11 | 2016-12-09 | 2016-11-15 | 2016-10-17 | 0.51 | No Change QoQ | |||
| 2016-08-11 | 2016-09-09 | 2016-08-15 | 2016-06-20 | 0.51 | No Change QoQ | |||
| 2016-05-11 | 2016-06-10 | 2016-05-13 | 2016-05-02 | 0.51 | No Change QoQ | |||
| 2016-02-10 | 2016-03-10 | 2016-02-12 | 2015-12-08 | 0.51 | Increase | |||
| 2015-11-11 | 2015-12-10 | 2015-11-13 | 2015-10-19 | 0.5 | No Change QoQ | |||
| 2015-08-12 | 2015-09-10 | 2015-08-14 | 2015-06-15 | 0.5 | No Change QoQ | |||
| 2015-05-14 | 2015-06-10 | 2015-05-18 | 2015-05-04 | 0.5 | No Change QoQ | |||
| 2015-02-11 | 2015-03-10 | 2015-02-13 | 2014-12-15 | 0.5 | Increase | |||
| 2014-11-12 | 2014-12-10 | 2014-11-14 | 2014-10-20 | 0.49 | No Change QoQ | |||
| 2019-11-14 | 2019-12-10 | 2019-11-15 | 2019-10-21 | 0.645 | Cash | |||
| 2019-11-14 | 2019-12-10 | 2019-11-15 | 2019-10-21 | 0.645 | Cash | |||
| 2020-02-13 | 2020-03-10 | 2020-02-14 | 2019-12-16 | 0.74 | Cash | |||
| 2020-05-14 | 2020-06-10 | 2020-05-15 | 2020-05-04 | 0.74 | Cash | |||
| 2020-08-13 | 2020-09-10 | 2020-08-14 | 2020-07-15 | 0.74 | Cash | |||
| 2020-11-12 | 2020-12-10 | 2020-11-13 | 2020-10-19 | 0.74 | Cash | |||
| 2021-02-11 | 2021-03-10 | 2021-02-12 | 2020-12-14 | 0.85 | Cash | |||
| 2021-05-13 | 2021-06-10 | 2021-05-14 | 2021-05-03 | 0.85 | Cash | |||
| 2021-08-12 | 2021-09-10 | 2021-08-13 | 2021-06-29 | 0.85 | Cash | |||
| 2021-11-12 | 2021-12-10 | 2021-11-15 | 2021-10-18 | 0.85 | Cash | |||
| 2022-02-14 | 2022-03-10 | 2022-02-15 | 2021-12-13 | 0.98 | Cash | |||
| 2022-05-13 | 2022-06-10 | 2022-05-16 | 2022-05-02 | 0.98 | Cash | |||
| 2022-08-12 | 2022-09-09 | 2022-08-15 | 2022-06-27 | 0.98 | Cash | |||
| 2022-11-14 | 2022-12-09 | 2022-11-15 | 2022-10-17 | 0.98 | Cash | |||
| 2023-02-14 | 2023-03-10 | 2023-02-15 | 2022-12-12 | 1.13 | Cash | |||
| 2023-05-12 | 2023-06-09 | 2023-05-15 | 2023-05-01 | 1.13 | Cash | |||
| 2023-08-14 | 2023-09-08 | 2023-08-15 | 2023-06-26 | 1.13 | Cash | |||
| 2023-11-14 | 2023-12-08 | 2023-11-15 | 2023-11-01 | 1.13 | Cash | |||
| 2024-02-14 | 2024-03-08 | 2024-02-15 | 2023-12-08 | 1.3 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|